Sho Sakui

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label study.

Teduglutide in pediatric patients under 10 kg with short bowel syndrome on parenteral support: An open-label study.

Journal: Pediatrics international : official journal of the Japan Pediatric Society

Published: July 10, 2025

One-year follow-up of the immunogenicity and safety of a first and second booster dose of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Final report of a phase 3 open-label trial.

One-year follow-up of the immunogenicity and safety of a first and second booster dose of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Final report of a phase 3 open-label trial.

Journal: Vaccine

Published: October 31, 2024

Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial.

Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial.

Journal: Vaccine

Published: October 22, 2023

Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support.

Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support.

Journal: Journal of pediatric gastroenterology and nutrition

Published: June 26, 2023

One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial.

One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial.

Journal: Vaccine

Published: May 26, 2023

Principal quantile treatment effect estimation using principal scores.

Principal quantile treatment effect estimation using principal scores.

Journal: Statistics in medicine

Published: February 14, 2023

Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.

Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.

Journal: Vaccine

Published: December 11, 2022

Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.

Safety and immunogenicity of NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Interim report of a phase I/II randomized controlled trial.

Journal: Vaccine

Published: January 21, 2022

A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.

A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.

Journal: Vaccine

Published: November 12, 2021

Showing 1-9 of 9

Last Updated: 09/26/2026